Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

by Bao, Hong , Zhao, Ren , Mei, Shuya , Gui, Honglian , Feng, Haiyan , Zhang, Qin , Zhang, Yifei , Xie, Qing , Shi, Yiqing , Xu, Yiping , Gao, Yuan , Jiang, Yimei , Gao, Yueqiu , Gao, Weiyi , Cui, Zhilei , Chen, Peizhan , Sun, Jing , Cao, Zhujun , Meng, Xianmin , Song, Zijia , Wang, Weijing , Ning, Guang

in Administration, Oral / Adult / Antiretroviral drugs / Antiviral Agents - administration & dosage / Antiviral Agents - adverse effects / Antiviral Agents - therapeutic use / Antiviral drugs / Coronavirus / Coronaviruses / COVID-19 / COVID-19 - virology / COVID-19 Drug Treatment - methods / Disease Progression / Global Health / Humans / Hypotheses / Infectious Disease / Infectious Disease General / Life sciences / Original / Pandemics / Review boards / Ritonavir / Ritonavir - administration & dosage / Ritonavir - adverse effects / Ritonavir - therapeutic use / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Single-Blind Method / Viral Infections

2023

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

2023

Confirm

Do you wish to request the book?

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

2023

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

Bao, Hong,

Zhao, Ren,

Mei, Shuya,

Gui, Honglian,

Feng, Haiyan,

Zhang, Qin,

Zhang, Yifei,

Xie, Qing,

Shi, Yiqing,

Xu, Yiping,

Gao, Yuan,

Jiang, Yimei,

Gao, Yueqiu,

Gao, Weiyi,

Cui, Zhilei,

Chen, Peizhan,

Sun, Jing,

Cao, Zhujun,

Meng, Xianmin,

Song, Zijia,

Wang, Weijing,

Ning, Guang

2023

Overview

In a trial in China involving participants with symptomatic mild-to-moderate Covid-19, VV116 (an oral analogue of remdesivir) was noninferior to nirmatrelvir–ritonavir with respect to the time to sustained clinical recovery.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Administration, Oral

/ Adult

/ Antiretroviral drugs

/ Antiviral Agents - administration & dosage

/ Antiviral Agents - adverse effects

/ Antiviral Agents - therapeutic use

/ Antiviral drugs